‌

US Patent 10677803 Method of assessing risk of PML

Patent 10677803 was granted and assigned to Biogen on June, 2020 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

Patent

Patent attributes

Patent Applicant

Biogen

Current Assignee

Biogen

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

106778030

Date of Patent

June 9, 2020

Patent Application Number

161153500

Date Filed

August 28, 2018

Patent Citations Received

‌

US Patent 12105090 Methods of treating a multiple sclerosis patient with anti-VLA-4 therapy

‌

US Patent 11292845 Methods of treating inflammatory and autoimmune diseases with natalizumab

‌

US Patent 11333670 Methods of treating inflammatory and autoimmune diseases with natalizumab

‌

US Patent 12066442 Method of assessing risk of PML

‌

US Patent 11280794 Method of assessing risk of PML

‌

US Patent 11287423 Assay for JC virus antibodies

Patent Primary Examiner

‌

Barry A Chestnut

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10677803 Method of assessing risk of PML

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API